High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis

Objective Phagocyte-derived myeloperoxidase (MPO) and pro-inflammatory high density lipoprotein (HDL) associate with rheumatoid arthritis (RA), but the link between MPO and HDL has not been systematically examined. In this study, we investigated whether MPO can oxidise HDL and determined MPO-specific oxidative signature by apoA-1 by peptide mapping in RA subjects with and without known cardiovascular disease (CVD). Methods Two MPO oxidation products, 3-chlorotyrosine and 3-nitrotyrosine, were quantified by tandem mass spectrometry (MS/MS) in in vitro model system studies and in plasma and HDL derived from healthy controls and RA subjects. MPO levels and cholesterol efflux were determined. Site-specific nitration and chlorination of apoA-1 peptides were quantified by MS/MS. Results RA subjects demonstrated higher levels of MPO, MPO-oxidised HDL and diminished cholesterol efflux. There was marked increase in MPO-specific 3-chlorotyrosine and 3-nitrotyrosine content in HDL in RA subjects consistent with specific targeting of HDL, with increased nitration in RA subjects with CVD. Cholesterol efflux capacity was diminished in RA subjects and correlated inversely with HDL 3-chlorotyrosine suggesting a mechanistic role for MPO. Nitrated HDL was elevated in RACVD subjects compared with RA subjects without CVD. Oxidative peptide mapping revealed site-specific unique oxidation signatures on apoA-1 for RA subjects with and without CVD. Conclusions We report an increase in MPO-mediated HDL oxidation that is regiospecific in RA and accentuated in those with CVD. Decreased cholesterol efflux capacity due to MPO-mediated chlorination is a potential mechanism for atherosclerosis in RA and raises the possibility that oxidant resistant forms of HDL may attenuate this increased risk.

[1]  M. Reilly,et al.  Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. , 2012, Atherosclerosis.

[2]  H. Paulus,et al.  Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[3]  S. Pennathur,et al.  Myeloperoxidase Targets Apolipoprotein A-I, the Major High Density Lipoprotein Protein, for Site-Specific Oxidation in Human Atherosclerotic Lesions* , 2012, The Journal of Biological Chemistry.

[4]  S. Pennathur,et al.  Myeloperoxidase Targets Apolipoprotein A-I , the Major HDL Protein , for Site-Specific Oxidation in Human Atherosclerotic Lesions , 2012 .

[5]  E. Sato,et al.  Increased myeloperoxidase plasma levels in rheumatoid arthritis , 2012, Rheumatology International.

[6]  G. Francis,et al.  Lipid-bound apolipoproteins in tyrosyl radical-oxidized HDL stabilize ABCA1 like lipid-free apolipoprotein A-I , 2012, BMC Biochemistry.

[7]  S. Blankenberg,et al.  Pathogenic Cycle Between the Endogenous Nitric Oxide Synthase Inhibitor Asymmetrical Dimethylarginine and the Leukocyte-Derived Hemoprotein Myeloperoxidase , 2011, Circulation.

[8]  J. Heinecke,et al.  Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. , 2011, Journal of proteomics.

[9]  A. Akhmedov,et al.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. , 2011, The Journal of clinical investigation.

[10]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[11]  P. Toth Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis , 2011 .

[12]  S. Pennathur,et al.  Quantitative analysis of amino Acid oxidation markers by tandem mass spectrometry. , 2011, Methods in enzymology.

[13]  L. Alfredsson,et al.  Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006 , 2010, Journal of internal medicine.

[14]  Roger E Bumgarner,et al.  High-Density Lipoprotein Suppresses the Type I Interferon Response, a Family of Potent Antiviral Immunoregulators, in Macrophages Challenged With Lipopolysaccharide , 2010, Circulation.

[15]  W. Robinson,et al.  Rheumatoid Arthritis: A Role for Immunosenescence? , 2010, Journal of the American Geriatrics Society.

[16]  M. Kaplan Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. , 2010, Rheumatic diseases clinics of North America.

[17]  D. Rader,et al.  The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[18]  D. Symmons,et al.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis , 2009, Annals of the rheumatic diseases.

[19]  H. Paulus,et al.  Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[20]  L. Trinquart,et al.  Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. , 2009, Rheumatology.

[21]  N. Brot,et al.  Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I , 2008, Proceedings of the National Academy of Sciences.

[22]  J. Eiserich,et al.  Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[23]  A. Tall,et al.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.

[24]  B. Fagerberg,et al.  Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr Published, JLR Papers in Press, November 18, 2007. , 2008, Journal of Lipid Research.

[25]  S. Hazen,et al.  The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction , 2007, Nature Structural &Molecular Biology.

[26]  B. Hahn,et al.  The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. , 2007, Journal of autoimmunity.

[27]  K. Kalunian,et al.  Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[28]  H. Klemm,et al.  Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase , 2006, Circulation.

[29]  J. Voss,et al.  Tyrosine 192 in Apolipoprotein A-I Is the Major Site of Nitration and Chlorination by Myeloperoxidase, but Only Chlorination Markedly Impairs ABCA1-dependent Cholesterol Transport* , 2005, Journal of Biological Chemistry.

[30]  Michael Kinter,et al.  Localization of Nitration and Chlorination Sites on Apolipoprotein A-I Catalyzed by Myeloperoxidase in Human Atheroma and Associated Oxidative Impairment in ABCA1-dependent Cholesterol Efflux from Macrophages* , 2005, Journal of Biological Chemistry.

[31]  A. Chait,et al.  Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.

[32]  A. Chait,et al.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Michael Kinter,et al.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.

[34]  J. Heinecke,et al.  Lysine Residues Direct the Chlorination of Tyrosines in YXXK Motifs of Apolipoprotein A-I When Hypochlorous Acid Oxidizes High Density Lipoprotein* , 2004, Journal of Biological Chemistry.

[35]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[36]  G L Freeman,et al.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.

[37]  E J Topol,et al.  Association between myeloperoxidase levels and risk of coronary artery disease. , 2001, JAMA.

[38]  W. Parks,et al.  Hypochlorous Acid Oxygenates the Cysteine Switch Domain of Pro-matrilysin (MMP-7) , 2001, The Journal of Biological Chemistry.

[39]  P. Venge,et al.  Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. , 1999, Rheumatology.

[40]  G. Francis,et al.  Enhanced Cholesterol Efflux by Tyrosyl Radical-oxidized High Density Lipoprotein Is Mediated by Apolipoprotein AI-AII Heterodimers* , 1998, The Journal of Biological Chemistry.

[41]  S. L. Hazen,et al.  3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.

[42]  J. Berliner,et al.  The role of oxidized lipoproteins in atherogenesis. , 1996, Free radical biology & medicine.

[43]  A. Daugherty,et al.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.

[44]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[45]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[46]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.